Alpha Teknova, Inc. announced its financial results for the first quarter ended March 31, 2025, reporting total revenue of $9.8 million. This represents a 5% increase compared to $9.3 million in the first quarter of 2024.
Lab Essentials revenue increased 12% to $8.1 million in Q1 2025 from $7.3 million in Q1 2024. Clinical Solutions revenue, however, decreased 32% to $1.2 million compared to $1.7 million in the prior-year quarter.
Gross profit for the first quarter 2025 improved to $3.0 million, resulting in a gross margin of 30.7%, up from $2.2 million and 23.8% margin in Q1 2024. The net loss for the quarter was $4.6 million, or negative $0.09 per diluted share, an improvement from $8.1 million, or negative $0.20 per diluted share, in Q1 2024.
Adjusted EBITDA improved to negative $2.5 million from negative $3.8 million year-over-year, and free cash outflow decreased to negative $4.3 million from negative $6.7 million. The company also reaffirmed its fiscal 2025 revenue guidance of $39 million to $42 million and anticipates full-year free cash outflow of less than $12 million.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.